Orkla India IPO Listing Today: Shares List at 2.75–3% Premium, Slip Up to 7% Intraday; GMP, Subscription & Analyst Views (Nov 6, 2025)

Orkla India IPO Listing Today: Shares List at 2.75–3% Premium, Slip Up to 7% Intraday; GMP, Subscription & Analyst Views (Nov 6, 2025)

MUMBAI | Thursday, November 6, 2025 — Packaged‑foods maker Orkla India made a muted stock‑market debut on Thursday, listing at a modest premium to the IPO price before giving up gains during the session. The stock opened at ₹750.10 on the NSE and ₹751.50 on the BSE vs an issue price of ₹730, but later slipped below the IPO price, underperforming grey‑market expectations that had signaled a stronger start. [1]


Listing day snapshot

  • Open: ₹750.10 (NSE), ₹751.50 (BSE); Issue price: ₹730. [2]
  • Intraday pressure: Within the first hour, the stock fell as much as ~7% from the listing price, hitting ₹697.15 on BSE and ₹702.85 on NSE, indicating a slide below the issue price. [3]
  • Expectations vs reality: Ahead of listing, the grey market premium (GMP) hovered around ₹66 (~9%), implying an indicative price near ₹796—well above the actual open. [4]
  • Market cap on listing: About ₹10,294.74 crore, per early‑session estimates. [5]
  • Listing mechanics: Shares admitted to trading on BSE (‘B’ Group) and NSE; stock participated in the Special Pre‑open Session (SPOS). [6]

IPO by the numbers

  • Offer size:₹1,667.54 crore, a 100% Offer for Sale (OFS) of 2.28 crore shares; no fresh issue proceeds to the company. Price band: ₹695–₹730. Lot size: 20 shares (min retail outlay ₹14,600 at upper band). [7]
  • Subscription strength:48.7× overall; QIB 117.63×, NII 54.42×, Retail 7.05–7.06×, Employees 15.12×. Bidding window ran Oct 29–31; allotment was Nov 3; listingNov 6. [8]
  • Intermediaries:BRLMs — ICICI Securities, Citigroup Global Markets India, J.P. Morgan India, Kotak Mahindra Capital; Registrar:KFin Technologies. [9]
  • Anchors: Raised about ₹499.6 crore from 30 anchor investors on Oct 28 by allotting 68.43 lakh shares at ₹730. [10]

Why the debut felt “lukewarm”

The listing premium of 2.75–3% was well below the ₹66 (~9%) GMP seen ahead of trade, signaling tempered secondary‑market appetite despite a blockbuster subscription book. As trading progressed, profit‑taking and broader market softness saw the stock reverse into the red, at one point down ~6–7% from the open. [11]


Company at a glance: brands & footprint

Orkla India—backed by Norway’s Orkla ASA—houses MTR Foods, Eastern Condiments and Rasoi Magic, spanning spices, masalas, ready‑to‑cook/ready‑to‑eat mixes, breakfast mixes and more. The business is organized into three units (MTR, Eastern, International) and exports to 40+ countries. Recent disclosures indicate double‑digit PAT margins (~10.7%) and steady topline growth. [12]


What analysts are saying

Early broker commentary framed the debut as “decent but below GMP hopes.” One view suggested partial profit‑booking by allottees with a disciplined stop‑loss, while another advised holding for the long term given Orkla India’s category leadership and the secular shift toward branded packaged foods. (Paraphrased from broker notes reported in the press.) [13]


Grey market vs. street: the gap explained

GMPs reflect unofficial sentiment and can soften into listing, especially when market mood is cautious. Today’s outcome underscores that oversubscription ≠ outsized listing pop; post‑listing price discovery still hinges on fundamentals, flows and day‑of sentiment. [14]


Key takeaways for investors (Nov 6, 2025)

  • Strong book, soft pop: Despite 48.7× bids, listing gains stayed low‑single‑digit. [15]
  • Quick reversal: The stock slid below the issue price intraday, at one point down ~7% from the open. [16]
  • Pure OFS:No fresh capital to the company; proceeds go to selling shareholders. [17]
  • Brand strength remains a pillar: A portfolio led by MTR and Eastern positions Orkla India to ride packaged‑food penetration trends. [18]

Context & chronology (all times IST, Nov 6)

  • 09:55–10:00 — Lists at ₹750.10 (NSE), ₹751.50 (BSE). [19]
  • ~10:20–11:10 — Shares trade lower; day’s low updates include ₹715 (early) and later ₹697.15/₹702.85 (BSE/NSE). [20]
  • Afternoon — Media characterizes debut as “lukewarm”/“muted” versus GMP‑implied pricing. [21]

The bottom line

Orkla India’s Dalal Street debut on November 6, 2025 mirrors a year in which subscription heat hasn’t always translated into splashy listing gains. With a pure OFS and brand‑rich portfolio, the stock now shifts from IPO mode to earnings execution—where margins, distribution expansion and product innovation will likely drive the narrative from here. [22]

Disclaimer: This article is for news and informational purposes only and is not investment advice. Markets are volatile; please consult a qualified advisor before making investment decisions.

References

1. www.business-standard.com, 2. www.business-standard.com, 3. www.financialexpress.com, 4. www.business-standard.com, 5. www.moneycontrol.com, 6. www.livemint.com, 7. www.business-standard.com, 8. www.business-standard.com, 9. groww.in, 10. www.business-standard.com, 11. www.business-standard.com, 12. groww.in, 13. www.business-standard.com, 14. www.business-standard.com, 15. www.business-standard.com, 16. www.financialexpress.com, 17. www.business-standard.com, 18. groww.in, 19. www.business-standard.com, 20. www.business-standard.com, 21. www.livemint.com, 22. www.business-standard.com

Stock Market Today

  • Arhaus, Inc. (ARHS) Beats Q3 EPS and Revenue; Zacks Rank #2 Buy Ahead of Outlook
    November 6, 2025, 10:42 AM EST. Arhaus, Inc. (ARHS) reported Q3 earnings of $0.09 per share, beating the Zacks Consensus by $0.01 and posting a +12.5% surprise from a year ago. Revenue was $344.57 million, topping estimates by about 1%. The company has exceeded EPS estimates in three of the last four quarters and has beat revenue estimates in two of the last four. Year-to-date, ARHS has risen about 3.8%, underperforming the S&P 500's gain of ~15.6%. Ahead of the call, the Zacks Rank remains #2 Buy. For the coming quarter, consensus is $0.10 per share on $348.02 million in revenue, and full-year guidance sits at $0.45 on $1.36 billion in revenue. Management commentary will shape the near-term outlook.
  • Epam (EPAM) Q3 Earnings Beat; Revenue Rises, But Stock Faces Mixed Outlook
    November 6, 2025, 10:40 AM EST. Epam (EPAM) reported Q3 earnings of $3.08 per share, beating the Zacks Consensus Estimate of $3.02 and delivering a +1.99% surprise. Revenue reached $1.39 billion, ahead of the consensus by 1.44% versus $1.17 billion a year ago. The company has topped estimates in all four of the past four quarters. Despite the beat, shares are down about 31.2% year-to-date as the broader market climbs. Outlook signs show a current-quarter consensus of $2.90 on $1.38 billion in revenue and a full-year view of $11.11 on $5.41 billion. Market focus will shift to management commentary for earnings trajectory and any revisions to the IT Services outlook and estimates.
  • Cars.com Q3 Results: Revenue In Line, EBITDA Beat, Margin Expansion
    November 6, 2025, 10:38 AM EST. Cars.com (NYSE:CARS) reported a Q3 that largely met expectations on revenue and adjusted earnings, while delivering a clear EBITDA beat and margin expansion. Revenue was $181.6 million, essentially in line with consensus of $181.4 million. Adjusted EPS came in at $0.48 vs $0.49 expected. Adjusted EBITDA totaled $54.63 million, ahead of the $53.51 million estimate, with a 30.1% EBITDA margin and Operating Margin of 9.3% (up from 6.4% a year ago). Free Cash Flow Margin jumped to 29% from 10.2%. Dealer Customers rose to 19,526, up 271 YoY. The company's current Market Capitalization is about $639.6 million. Looking ahead, analysts see about 2.4% revenue growth over the next 12 months, with modest long-term growth versus peers.
  • Thermon THR Q3 2025 Beats Estimates; Raises Revenue and EPS Guidance
    November 6, 2025, 10:36 AM EST. Thermon (NYSE:THR) delivered a strong Q3 CY2025, topping estimates with revenue of $131.7 million, up 14.9% YoY. The company's non-GAAP EPS of $0.55 beat consensus by 51.7%, and Adjusted EBITDA reached $30.61 million, well above expectations. Management lifted the full-year revenue guidance to a midpoint of $516.5 million and increased the midpoint Adjusted EPS guidance to $2.08, signaling improved profitability and cash generation. The quarter's operating margin was 16.4%, while free cash flow margin stood at 3.3%. With a market cap near $972 million, Thermon remains a proxy for demand in engineered industrial process heating.
  • BMO Cuts TrueBlue Price Target to $6, Maintains Outperform
    November 6, 2025, 10:32 AM EST. TrueBlue (TBI) received a price-target cut from $8.00 to $6.00 from BMO Capital Markets, which still carries an outperform rating and sees about an 8.3% upside from the prior close. Weiss Ratings reiterated a 'sell (d-)' on the stock. MarketBeat consigns a consensus Hold and a $6.00 target, with one firm rated Buy and another Sell. The stock opened at $5.54. Key metrics show debt-to-equity 0.18, quick ratio 1.94, current ratio 1.94; market cap ~$165.7 million; P/E not profitable at -4.82 and a beta of 1.55. Q earnings of $0.03 beat estimates by $0.12 on $431.27 million revenue; analysts expect about $0.15 per share for the year.
Investors Beware: 7 Stocks to Avoid on October 22, 2025 Amid Alarming Warnings
Previous Story

Michael Burry’s $1.1 Billion AI ‘Short’ Jolts Global Markets: Nvidia, Palantir Lead Tech Slide — What to Watch Today (Nov. 6, 2025)

Groww IPO Day 2: Fully Subscribed (1.47x); Retail 4.65x, GMP 11–15%; Nithin Kamath Says 20% of Applications Came via Zerodha — What Top Brokerages Recommend
Next Story

Groww IPO Day 2: Fully Subscribed (1.47x); Retail 4.65x, GMP 11–15%; Nithin Kamath Says 20% of Applications Came via Zerodha — What Top Brokerages Recommend

Go toTop